Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings

por Wilson, S, Tod, M, Ouerdani, A, Emde, A, Yarden, Y, Adda Berkane, A, Kassour, S, Wei, MX, Freyer, G, You, B, Grenier, E, Ribba, B
Publicado 2015